Status:
COMPLETED
Dexmedetomidine Facilitate Analgesia
Lead Sponsor:
China International Neuroscience Institution
Conditions:
Lower Limb Fracture
Nerve Block
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
Pre-clinic evidences showed that DEX produces antinociception by inhibiting the activation of spinal microglia and astrocyte decreasing noxious stimuli evoked release of nociceptive substances and fur...
Detailed Description
Pre-clinic evidences showed that DEX produces antinociception by inhibiting the activation of spinal microglia and astrocyte decreasing noxious stimuli evoked release of nociceptive substances and fur...
Eligibility Criteria
Inclusion
- aged from 18 to 80 years old
- American Association of anesthesiologists (ASA) grade Ⅱ \~ IV
- body mass index (BMI) 18.5-40
- planning undergoing peripheral nerve block
Exclusion
- incomplete effect of nerve block
- Alzheimer's disease
- implanted cardiac pacemakers
- mental illness
- epilepsy
- autonomic nervous system diseases
- projected the duration of the operation was more than 3 hours
Key Trial Info
Start Date :
January 19 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 3 2021
Estimated Enrollment :
181 Patients enrolled
Trial Details
Trial ID
NCT04675372
Start Date
January 19 2021
End Date
August 3 2021
Last Update
August 5 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
China International Neuroscience
Beijing, Beijing Municipality, China, 100053